Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 10, 2000, Pages 3526-3530

  Ibáñez, Lourdes ^a   Valls, Carme ^a   Potau, Neus ^b   Marcos, Maria Victoria ^c   De Zegher, Francis ^d,e  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Endocrinology Unit   (Spain)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e FUND FOR SCIENTIFIC RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; CHOLESTEROL; DIANBEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYPROGESTERONE; LEUPRORELIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; METFORMIN; PRASTERONE; PRASTERONE SULFATE; TESTOSTERONE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; GASTROINTESTINAL SYMPTOM; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERINSULINISM; INSULIN RESISTANCE; INSULIN RESPONSE; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRECOCIOUS PUBERTY; PRIORITY JOURNAL;

EID: 0033756465     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.10.3526     Document Type: Article

References (56)

1. Androgens in adrenarche and pubarche
2. Precocious pubarche, hyperinsulinism and ovarian hyperandrogenism in girls: Relation to reduced fetal growth
3. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion
4. Anovulation after precocious pubarche: Early markers and time course in adolescence
5. Postpubertal outcome in girls diagnosed of premature pubarche during childhood: Increased incidence of functional ovarian hyperandrogenism
6. Hyperinsulinemia and decreased insulin-like growth factor binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche
7. Hyperinsulinemia, dyslipaemia and cardiovascular risk in girls with a history of premature pubarche
8. Hyperinsulinemia as an independent risk factor for ischemic heart disease
9. Hyperinsulinemia: The key feature of a cardiovascular and metabolic syndrome
10. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: A 21-year follow-up of 8000 men
11. Hormonal effects of flutamide in young women with polycystic ovary syndrome
12. The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome
13. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia and hyperinsulinism in nonobese, adolescent girls: Effect of flutamide
14. Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome
15. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism
16. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications
17. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis
18. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism
19. Induction of steroidogenic enzyme genes by insulin and IGF-I in cultured adult human adrenocortical cells
20. Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome
21. Insulin infusion amplifies 17α-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: Apparent relative impairment of 17,20 lyase activity
22. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein
23. Regulation of sex hormone-binding globulin production by growth factors
24. Metformin therapy in polycystic ovary syndrome reduced hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy
25. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens
26. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation
27. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome
28. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome
29. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome
30. Can metformin reduce insulin resistance in polycystic ovary syndrome?
31. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome
32. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome
33. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome
34. Clinical assessment of body hair growth in women
35. Source localization of androgen excess in adolescent girls
36. Normal and almost normal precocious variations in pubertal development. Premature pubarche and premature thelarche revisited
37. Standardized percentile curves of body mass index for children and adolescents
38. Genotyping steroid 21-hydroxylase deficiency: Hormonal reference data
39. 5-steroid levels
40. Insulin resistance: Classification, prevalence, clinical manifestations, and diagnosis
41. Sexual dimorphism in the maturation of the pituitary-gonadal axis, assessed by gonadotropin-releasing hormone agonist challenge
42. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
43. Drug therapy. Metformin
44. Stimulation of the intracellular portion of the human insulin receptor by the antidiabetic drug metformin
45. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome
46. Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinemia or lean normoinsulinemia
47. Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome
48. The treatment of insulin resistance does not improve adrenal cytochrome P450c17α enzyme dysregulation in polycystic ovary syndrome
49. Editorial: Evidence that idiopathic functional adrenal hyperandrogenism is caused by dysregulation of adrenal steroidogenesis and that hyperinsulinemia may be involved
50. Supraphysiological hyperinsulinemia acutely increases hypothalamic-pituitary-adrenal secretory activity in humans
51. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells
52. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system
53. Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance
54. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein (a) and immunoreactive insulin levels in patients with polycystic ovary syndrome
55. Hypofibrinolytic amd atherogenic risk factors for stroke
56. Precocious pubarche, dyslipidemia, and low IGF binding protein-1 in girls: Relation to reduced prenatal growth